Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- IBL: ADAMTS5 Test Kit for Predicting Efficacy of Biologic Treatments in RA
February 22, 2012
- Glivec Receives Add’l Indication for HES/CEL: Novartis Pharma
February 22, 2012
- Cellectis of France Surrenders Claim for Damages Against Shionogi
February 22, 2012
- DSP Obtains Approval for Myslee Generic, Boosting Efforts to Strengthen CNS Field
February 21, 2012
- Pfizer Japan, DSP Apply for Pediatric Indication for Norvasc and Amlodin Based on Data from Public Domain
February 21, 2012
- Astellas, SKK Announce Alliance in Field of Kidney Diseases
February 21, 2012
- Nichi-Iko Makes Yakuhan Subsidiary to Expand Disinfectant Lineup
February 21, 2012
- Kowa Launches Livalo in Mexico through Eli Lilly
February 21, 2012
- Sales of DPP-4 Inhibitors Reach ¥100 Billion Level, Antidiabetic Drugs Show Double-Digit Growth: IMS Japan
February 20, 2012
- Pfizer Japan Ranked No. 1 as Promotion Company: IMS Japan
February 20, 2012
- Qol President Nakamura Says “Proactive Cooperation” Needed for Distribution Improvement
February 20, 2012
- Daiichi Sankyo, Roche Announce Approval of Malignant Melanoma Treatment Vemurafenib in EU
February 20, 2012
- Diabetes Treatments: Their Development and Market
February 20, 2012
- With Upcoming Price Cuts, Nursing Homes Present Opportunity for Makers of Generic AD Treatments
February 20, 2012
- Fuso Acquires Exclusive Domestic Marketing Rights to Mucus Bulging Agent
February 20, 2012
- 6 SGLT-2 Inhibitors in Final Development Stage, Applications Expected in 2013
February 17, 2012
- Qol Expects to Clear “30%” Generic Dispensing Mark Around October
February 17, 2012
- 40% of Doctors Prescribe Existing Drugs Until New Drug Information Is Clarified: Survey
February 17, 2012
- Daiichi Sankyo, Pfizer Obtain Approval for Their Competition Generics for June Listing
February 17, 2012
- Drugstore Chains to Appeal Directly to Public in Support of “Dispensing Point” Services
February 17, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…